.png?v=8c6527571d76e5472f015e54a39d96e5)
Standing Strong on Ovarian Cancer Day
Standing Strong on Ovarian Cancer Day: ICON's Commitment to Advancing Care
Ovarian cancer remains one of the most challenging gynaecologic malignancies, both in terms of detection and treatment. Globally, it is the eighth most common cancer in women, with nearly 350,000 new cases reported each year. Despite progress in oncology, survival outcomes remain tightly linked to the timing of diagnosis.
A Disease Often Detected Too Late
The stark reality of ovarian cancer is its silent progression. Symptoms like bloating, abdominal discomfort, and changes in appetite are vague and often attributed to less serious conditions. As a result, only about 20% of ovarian cancer cases are detected at an early stage. This delay in diagnosis has profound consequences: five-year survival rates can range from as high as 93% when caught early to just 31% when detected late.
This challenge underscores the need for both public awareness and research into better diagnostic tools. Biomarkers, imaging technology, and AI-driven screening methods are all areas of active investigation, but no standard screening method has yet been established for the general population. The lack of early detection tools remains one of the key barriers to improved survival rates.Hope on the Horizon
Fortunately, treatment options for ovarian cancer have expanded significantly in recent years. One of the most impactful developments has been the introduction of PARP inhibitors, which target cancer cells with BRCA mutations by interfering with their DNA repair mechanisms. Drugs such as olaparib and niraparib have brought real progress for patients with certain genetic profiles.
Martin noted, "Recent treatment advances have included PARP inhibitors, but there are many development programs looking at PD-1 inhibitor combinations and some Antibody Drug Conjugates (ADCs). One of our customers is particularly focused on immunotherapies and ADCs, so we are very excited to be part of their development program." Beyond PARP inhibitors, there is growing interest in immunotherapy and Antibody Drug Conjugates (ADCs). PD-1 and PD-L1 inhibitors, which help restore the immune system's ability to recognize and attack cancer cells, are currently being explored in combination with chemotherapy or targeted agents.ICON's Role in Advancing Research
At ICON, we are proud to contribute meaningfully to this evolving landscape. We are currently supporting development programs focused on immunotherapies and ADCs, working closely with leading biopharmaceutical sponsors. Our experience in oncology clinical trials—particularly in gynaecologic cancers—positions us as a key partner in the global fight against ovarian cancer. Martin emphasized, "ICON is highly engaged with the global Investigator community in gynaecologic/ovarian oncology research. We have made important contributions to 13 ovarian cancer studies where many patients from North America & EMEA have participated in our ovarian cancer trials." Collaborating with the World's Leading Cooperative Groups A cornerstone of our success is our close collaboration with respected research networks such as ENGOT (European Network for Gynaecological Oncological Trials) and GOG (Gynaecologic Oncology Group). These organizations are instrumental in running high-quality clinical trials and have been central to many of the advances in ovarian cancer care.
Martin shared, "ICON’s excellent delivery of ovarian cancer studies is strongly correlated with our engagement with co-operative groups, like ENGOT covering Spain, Italy, France, Czech Republic, UK, Israel or GOG covering USA and Canada. ICON is proud of our strong experience in engaging with these co-operative groups and the difference we are trying to bring to the lives of patients and their families." ENGOT brings together trial groups from multiple countries including Spain, Italy, France, the Czech Republic, the UK, and Israel, while GOG covers sites across the USA and Canada. Our long-standing partnerships with these groups help ensure that studies are executed efficiently and ethically, while staying deeply connected to local investigators and patients. By aligning with ENGOT and GOG, ICON facilitates research that is both global in scope and locally relevant. We are able to leverage these networks to streamline patient recruitment, support investigator engagement, and uphold the highest standards in data quality and patient safety.Why Our Work Matters
Every clinical trial represents more than data points. It represents a chance for a patient to access cutting-edge treatment, a family to find hope, and a community to move closer to a cure. At ICON, we never lose sight of the people behind the protocols. Our focus on collaboration, quality, and compassion drives our mission to improve patient outcomes.
We are especially proud of our efforts to foster inclusion in clinical trials, ensuring women from varied backgrounds and regions have access to potentially life-changing treatments. With every study we support, we strive to close the gap between medical research and the real-world needs of patients and caregivers.Looking to the Future
The fight against ovarian cancer is far from over, but progress is being made every day. Through our partnerships, scientific expertise, and unwavering dedication, ICON continues to push boundaries and make a meaningful difference in women’s health.
This Ovarian Cancer Day, we honour the courage of patients, the dedication of researchers, and the power of collaboration. We remain steadfast in our commitment to helping bring forward the next generation of therapies that will transform lives.Join Us in Making a Difference
Whether you are a clinician, researcher, or someone passionate about advancing healthcare, ICON offers opportunities to contribute to this important mission. Together, we can ensure that innovation reaches the women who need it most - faster, safer, and more effectively.
View our current job openings at ICON today.
Sign up for post alerts
ICON & You
The potential of together.
Careers that improve the lives of patients, our clients and each other. Are you ready to make a difference?
View jobsRelated jobs at ICON
Salary
Location
India, Chennai
Department
Full Service - Corporate Support
Location
Chennai
Remote Working
Office Based
Business Area
ICON Full Service & Corporate Support
Job Categories
Accounting & Finance
Job Type
Permanent
Description
Job Advert PostingThe Role We are looking for a candidate who can Build Report & Analyse financial results to leaders in the context of each Business unit objective.This person is also responsible for
Reference
JR133700
Expiry date
01/01/0001
Author
Puja JaiswalAuthor
Puja JaiswalSalary
Location
India, Chennai
Department
Clinical Trial Management
Location
Chennai
Remote Working
Office Based
Business Area
ICON Full Service & Corporate Support
Job Categories
Regulatory Document Management
Job Type
Permanent
Description
We are currently seeking a Senior TMF Specialist to join our diverse and dynamic team. As a Senior TMF Specialist at ICON, you will play a pivotal role in managing the Trial Master File (TMF) for clin
Reference
JR132671
Expiry date
01/01/0001

Author
Kavitha K
Author
Kavitha KSalary
Location
Serbia, Belgrade
Location
Belgrade
Remote Working
Office or Home
Business Area
ICON Strategic Solutions
Job Categories
Clinical Trial Support
Job Type
Permanent
Description
We are currently seeking a Clinical Trial Administrator to join our diverse and dynamic FSP team. As a Clinical Trial Administrator at ICON, you will play a pivotal role in assisting in the coordinati
Reference
JR135848
Expiry date
01/01/0001
Author
Dariusz SternlichtAuthor
Dariusz SternlichtSalary
Location
India, Bangalore
Location
Bangalore
Chennai
Trivandrum
Bengaluru
Remote Working
Office or Home
Business Area
ICON Full Service & Corporate Support
Job Categories
Clinical Programming
Job Type
Permanent
Description
We are currently seeking a Senior Statistical Programmer to join our diverse and dynamic team. As a Senior Statistical Programmer, you will lead and manage projects and program statistical analyses/re
Reference
JR133341
Expiry date
01/01/0001
Author
Kashifa TahseenAuthor
Kashifa TahseenRelated stories
.png)
Teaser label
Career ProgressionContent type
BlogsPublish date
09/19/2025
Summary
How to Build a Strong LinkedIn Profile That Attracts Employers LinkedIn is no longer just a digital CV. It is a professional network, a space to showcase your skills and a platform to connect with
.png)
Teaser label
Our PeopleContent type
BlogsPublish date
09/16/2025
Summary
Growing with ICON: Christina’s Journey in Clinical Operations and Quality Leadership At ICON, we are proud to showcase the incredible journeys of our colleagues who make a real impact on pati
.png)
Teaser label
IndustryContent type
BlogsPublish date
08/25/2025
Summary
Careers in Pharmacovigilance Pharmacovigilance, also known as drug safety, is one of the most important pillars of modern medicine. It ensures that once a medicine is developed, tested, and appro
Recently viewed jobs
Impactful work. Meaningful careers. Quality rewards.
At ICON, our employees are our greatest strength. That’s why we are committed to empowering you to live your best life, both inside and outside of work. Whether your ambition is lead a global team, become a deep scientific or technical expert, work in-house with our customers or gain experience in a variety of different ICON functions, we will support you in realising your full potential. See all locations Learn more about Our Culture at ICON